Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with
cognition. Currently, there are no FDA-approved treatments targeting cognitive function in
Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used
in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as
compared to treatment with a placebo pill in combination with standard anti-inflammatory
drugs in women with MS.